News
DRUG
1.046
+0.57%
0.006
Psychedelic drug developers could benefit from NIH funding for chronic pain
Healthcare Psychedelic drug developers could benefit from NIH funding for chronic pain. National Institutes of Health is offering $8.4M to support trials examining the efficacy and safety of psychedelic treatments for pain. The research can include psilocybin, LSD, mescaline, and MDMA.
Seeking Alpha · 3d ago
Weekly Report: what happened at DRUG last week (0422-0426)?
Weekly Report · 3d ago
Weekly Report: what happened at DRUG last week (0415-0419)?
Weekly Report · 04/22 09:40
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist on Hearings. The Drug Enforcement Administration is revisiting its stance on the classification of two psychedelic compounds. The agency has proposed both be listed as Schedule I substances with no recognized medical use. Benzinga Psychedelics Podcast features an expert on the ancient healing plant kanna.
Benzinga · 04/17 12:42
Weekly Report: what happened at DRUG last week (0408-0412)?
Weekly Report · 04/15 09:36
Weekly Report: what happened at DRUG last week (0401-0405)?
Weekly Report · 04/08 09:38
Weekly Report: what happened at DRUG last week (0325-0329)?
Weekly Report · 04/01 09:38
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Utah hospitals will soon provide psilocybin and MDMA therapy for mental health conditions in a pilot program. Beckley Psytech and atai announce positive initial results from a clinical trial of 5-MeO-DMT in Treatment Resistant Depression. Prosecutors in Virginia are probing whether Facebook's social media platforms are facilitating the illegal sale of drugs. Elon Musk makes the case for using psychedelics in a new episode of the Benzinga Psychedelics Podcast.
Benzinga · 03/29 16:43
Bright Minds Biosciences’ Successful AGM & Stock Options Grant
TipRanks · 03/27 21:07
Weekly Report: what happened at DRUG last week (0318-0322)?
Weekly Report · 03/25 09:39
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement. Psychedelics biopharma company Cybin Inc. Announced that the FDA has granted it a breakthrough therapy designation for its LSD-based treatment for anxiety disorder. The company also announced the pricing of an underwritten offering of $175 million in shares.
Benzinga · 03/20 18:49
Weekly Report: what happened at DRUG last week (0311-0315)?
Weekly Report · 03/18 09:38
'Indiana Lawmakers Send Psilocybin Research Funding Bill To Governor' - Marijuana Moment
Indiana lawmakers have sent a bill to the governor's desk to fund psychedelic research. The bill includes provisions to fund studies into psilocybin as a treatment for mental health conditions. The state is one of a growing number of states pursuing reform on psychedelics. Indiana lawmakers have been considering marijuana legalization.
Benzinga · 03/14 16:42
Weekly Report: what happened at DRUG last week (0304-0308)?
Weekly Report · 03/11 09:37
Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation
Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation. U.S. FDA issued breakthrough therapy designation for its LSD formulation for generalized anxiety disorder. After the announcement, Mind Medicine stock surged 55% to reach a new 52-week high. Other companies focused on psychedelic drugs also traded higher on Thursday.
Seeking Alpha · 03/07 16:29
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety Disorder. The medical psychedelics field is at a pivotal juncture. Clinical trial results show potential benefits for psilocybin therapy's potential for treatment of generalized anxiety disorder. Beckley Academy has published the first open-source learning framework to advance psychedelic-assisted therapy training standards. Enveric Biosciences has signed deals to license three types of drug compounds.
Benzinga · 03/04 18:48
Weekly Report: what happened at DRUG last week (0226-0301)?
Weekly Report · 03/04 09:38
Oregon House passes bill to end hard drug decriminalization
New Zealand this week reversed a ban on tobacco sales to younger generations. Thailand just announced that it would ban the use of recreational cannabis by the end of this year. Oregon is getting second thoughts on decriminalizing hard drugs. The first U.S. State to decriminalize hard drugs has declared a fentanyl state of emergency.
Seeking Alpha · 03/01 11:42
Weekly Report: what happened at DRUG last week (0219-0223)?
Weekly Report · 02/26 09:42
Weekly Report: what happened at DRUG last week (0212-0216)?
Weekly Report · 02/19 09:42
More
Webull provides a variety of real-time DRUG stock news. You can receive the latest news about Bright Minds Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About DRUG
Bright Minds Biosciences Inc. is a biotechnology company. The Company is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. It has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain. Its pipeline includes BMB-101, BMB-202, and BMB-xxx. BMB-101 is for the treatment of Dravet syndrome and other neurological and neuro-psychiatric disorders. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling while avoiding off-target effects.